Health Care [ 5/12 ] | Biotechnology [ 51/74 ]
NASDAQ | Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities.
The company was founded in 2018 and is based in Carmel, Indiana.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 26 | -0.51 Increased by +28.17% | -0.58 Increased by +12.07% |
| Mar 23, 26 | -0.49 Decreased by -4.26% | -0.60 Increased by +17.88% |
| Nov 6, 25 | -0.63 Increased by +77.34% | -0.68 Increased by +7.35% |
| Aug 7, 25 | -0.58 Increased by +94.94% | -0.77 Increased by +24.68% |
| May 12, 25 | -0.71 | -0.77 Increased by +7.79% |
| Mar 17, 25 | -0.47 | -0.59 Increased by +19.85% |
| Nov 7, 24 | -2.78 | -2.72 Decreased by -2.21% |
| Aug 28, 24 | -11.47 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -23.52 M Increased by +1.52% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by -100.00% | -22.06 M Decreased by -41.55% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -21.62 M Decreased by -19.16% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -19.41 M Decreased by -22.41% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -23.88 M Decreased by -93.56% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 222.00 K Increased by +N/A% | -15.59 M Decreased by -76.25% | Decreased by -7.02 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -18.14 M Decreased by -78.53% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -15.86 M Decreased by -108.43% | Decreased by N/A% - |